

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED

大成生化科技集團有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00809)

INSIDE INFORMATION PROFIT ALERT

This announcement is made by Global Bio-chem Technology Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Directors**”) wishes to inform the shareholders of the Company and potential investors that based on the preliminary review of the Group’s unaudited consolidated management accounts for the year ended 31 December 2023 (the “**Year**”) currently available, the Group is expected to record a net gain (excluding tax effect) in the range of approximately HK\$3,600.0 million to HK\$4,000.0 million for the Year, as compared with the net loss (excluding tax effect) of approximately HK\$1,573.8 million recorded for the year ended 31 December 2022 (the “**Corresponding Prior Year**”), for the Group’s continued and discontinued operations. The discontinued operations of the Group means the operations of Global Sweeteners Holdings Limited (“**GSH**”, together with its subsidiaries, the “**GSH Group**”), a company listed on the Main Board of the Stock Exchange (Stock Code: 03889), and its subsidiaries, which no longer form part of the Group upon completion of the disposal of the GSH Group by the Group (the “**GSH Completion**”) on 21 December 2023.

Such significant improvement is primarily attributable to the expected recognition by the Group of:

- (i) a one-off gain of not less than approximately HK\$4,000.0 million for the Year from the debt restructuring arrangements (the “**Debt Restructuring Arrangements**”) which includes (a) the transfer of the loans of the Group owed to 中國信達資產管理股份有限公司吉林省分公司 (Jilin Branch of China Cinda Asset Management Co., Ltd.*) with an aggregate outstanding principal of approximately RMB4,267.8 million, together with outstanding interest (the “**Entire Transferred Loans**”), to 吉林省農業投資集團有限公司 (Jilin Agricultural Investment Group

Co., Ltd.*) (“**Nongtou**”) on 31 December 2023; and (b) the entering into of the debt restructuring agreement on 31 December 2023 between Nongtou, as the then creditor, and several subsidiaries of the Group, as the debtors, in respect of the Entire Transferred Loans. Pursuant to the Debt Restructuring Arrangements, a major portion of the Entire Transferred Loans had been waived. For details of the Debt Restructuring Arrangements, please refer to the announcement of the Company dated 4 January 2024;

- (ii) a one-off gain of not less than approximately HK\$200.0 million for the Year from the GSH Completion;
- (iii) a one-off gain amounted to not less than approximately HK\$300.0 million for the Year in relation to the further extension of the maturity date of the convertible bonds issued by the Company to Modern Agricultural Industry Investment Limited in October 2015 from the extended maturity date of 15 June 2023 to 30 September 2025; and
- (iv) a one-off gain amounted to not less than approximately HK\$400.0 million from the derecognition of the assets and liabilities of 哈爾濱大成生物科技有限公司 (Harbin Dacheng Bio Technology Co., Ltd.*), an indirect wholly-owned subsidiary of the Company, during the Year.

As a result, the Group is expected to record a substantial improvement in its annual results for the Year as compared with the Corresponding Prior Year.

As at the date of this announcement, the Company is in the course of finalising its annual results for the Year. The information contained in this announcement is only based on the preliminary assessment by the management of the Group with reference to the unaudited consolidated management accounts of the Group for the Year and information currently available to it, which has not been confirmed or reviewed by the Company’s auditor. Shareholders of the Company and potential investors are advised to read carefully the final results announcement of the Company for the Year which is expected to be published by the end of March 2024 in compliance with the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Global Bio-chem Technology Group Company Limited
Wang Cheng
Chairman

Hong Kong, 29 February 2024

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Wang Cheng and Mr. Wang Guicheng; one non-executive Director, namely, Mr. Li Yuewen; and three independent non-executive Directors, namely, Ms. Jiang Fangfang, Mr. Tan Chao and Ms. Xie Liangqiu.

** For identification purposes only*